In the general population, both subcutaneous mastectomy and simple (total) mastectomy have been used for prophylaxis of breast cancer in BRCA1 and BRCA2 mutation carriers. Prophylactic risk-reducing mastectomy (RRM) strongly reduces the breast cancer risk, with about 90% at the age of 70 when ...
The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. Cancer Cell 2002;1:129 -32.Elledge SJ, Amon A. The BRCA1 suppressor hypothesis: An explana- tion for the tissue-specific tumor development in BRCA1 patients. Cancer Cell 2002; 1:129...
triple-negative breast cancer (TNBC;BRCA1), oestrogen receptor (ER)-positive breast cancer (BC), and human epidermal growth factor receptor 2 (HER2)-negative BC (BRCA2); however, all BC subtypes can occur in association with g
Approximately 30–50% of hereditary breast and ovarian cancer (HBOC) is due to the presence of germline pathogenic variants in the BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185) onco-suppressor genes, which are involved in DNA damage response. Women who carry pathogenic BRCA1 variants are partic...
It is unclear how genetic aberrations impact the state of nascent tumour cells and their microenvironment. BRCA1 driven triple negative breast cancer (TNBC) has been shown to arise from luminal progenitors yet little is known about how BRCA1 loss-of-func
1c, and the differential signals between BRCA1+/+ and BRCA1mut/+ were confirmed by locus-specific ChIP-qPCR (Fig. 1d). In contrast to the relatively large number of super-enhancers lost in BRCA1 mutation carriers, only 3 super-enhancers were gained in the mutation-carrying samples (Fig....
Take 6A. Wouldn't one normally run the control and BRCA1 IP lanes on the same gel, exactly as suggested by the arrangement of the lanes? And it is not obvious that the vertical "line" between middle and right lanes does extend through all slices (see XRHAMM slice), as the original ...
We explored the predictive significance of BRCA1, TXR1 and TSP1 expression in non-small-cell lung cancer (NSCLC) patients treated with docetaxel in association with cisplatin or gemcitabine. To analyse BRCA1, TXR1 and TSP1 mRNA expression from microdisse
BRCAness is defined as shared tumour characteristics between sporadic and BRCA-mutated cancers. However, how to exactly measure BRCAness and its frequency in breast cancer is not known. Assays to establish BRCAness would be extremely valuable for the cli